Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRESTO - CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AREATA (AA) PATIENTS TREATED WITH RITLECITINIB IN A REAL-WORLD (RW) COHORT: A MULTINATIONAL, PROSPECTIVE OBSERVATIONAL STUDY.

NCT06531109 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06531109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06531109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRESTO - CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AREATA (AA) PATIENTS TREATED WITH RITLECITINIB IN A REAL-WORLD (RW) COHORT: A MULTINATIONAL, PROSPECTIVE OBSERVATIONAL STUDY.
Lead sponsor
Pfizer
Phase
Observational
Overall status
Active, not recruiting
Start date
August 7, 2024
Completion date
April 15, 2028
Enrollment
450 (estimated)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata